SITC 2021 | TACTI-002 and TACTI-003: Eftilagimod alpha for metastatic head and neck squamous cell carcinoma

Frédéric Triebel, MD, PhD, Immutep, Paris, France, discusses the TACTI-002 (NCT03625323) and TACTI-003 (NCT04811027) trials, both of which had updates presented at SITC 2021. TACTI-002 is a Phase II trial investigating the use of eftilagimod alpha plus pembrolizumab in the second-line in patients with PD-L1 unselected metastatic head and neck squamous cell carcinoma. Current results show a doubling of overall response rate (ORR) and longer duration of response in these patients. These promising results lead to the fast-tracked FDA approval to use eftilagimod alpha in combination with pembrolizumab in the first-line setting. TACTI-003 investigated the use of pembrolizumab plus eftilagimod alpha vs pembrolizumab alone in patients with first-line metastatic/recurrent head and neck squamous cell carcinoma. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.